Fig. 5: Anti-Ly6a antibody has a strong immunotherapeutic effect even in mice resistant to anti-PD1 antibody treatment.

a Experimental flowchart. b Normalized mean numbers of B16F10 melanoma cells following co-culture with splenic CD8⁺ T cells from transgenic mice bearing gp100-reactive T cells in the presence of various clones of anti-Ly6a antibody or IgG control (n = 10 per group). c Mean tumor diameters (left) and data from individual mice (right) treated with UVB or mock-irradiated (control) and injected subcutaneously with Ret melanoma cells then treated with anti-Ly6a antibody or IgG control. Arrow indicates time of antibody injection (n = 6 per group). d Mean percentages of Granzyme B expression in tumor-infiltrating (left) or sDLN (skin Drained Lymph Nodes) (right) CD45⁺ cells (n = 5 per group). e Experimental flowchart. f Mean tumor diameters (left) and data for individual mice (right) injected with Ret melanoma cells and treated with anti-IFNR1, anti-Ly6a, or IgG (control) antibodies. The arrow indicates the day of treatment. (n = 6 per group). g Experimental flowchart. h Mean tumor diameters (left) and individual data (right) for mice injected with Ret melanoma cells and treated with anti-PD1, anti-PD-1, anti-Ly6a, or IgG (control) antibodies (n = 6 per group). Arrows indicate days of treatment. Statistical significance was determined by two-way ANOVA test with Tukey correction (b, c, f, h) or two-tailed t test (d). Error bars represent standard errors. Source data are provided as a Source Data file.